Skip to main content
Premium Trial:

Request an Annual Quote

OGT to Develop Single-Cell Gene Expression Method for EU Stem Cell Consortium

NEW YORK (GenomeWeb News) – Oxford Gene Technology said today it has joined a European consortium of universities and small- to mid-sized businesses focused on advancing knowledge of normal and abnormal stem cells.
The company said it will develop its single-cell technology for the EuroSyStem Consortium, which is a partnership funded by the EU's 7th Framework Program that provides facilities, resources, and training to the stem cell research community.
OGT said its role will be to develop its single-cell technology for quantitative determination of gene expression in order to examine the dynamic range of gene expression.
The technology will be applied to two separate stem cell systems, including erythropoetic stem cells research in the MRC Molecular Hematology Unit at Oxford, and mouse embryonic stem cells with the Wellcome Trust Centre for Stem Cell Research, Cambridge.
“We are confident that our single cell technology, with its unique ‘cell population census’ approach, will revolutionize gene expression analysis,” OGT Research and Development Director John Anson said in a statement.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.